Enterobacteriaceae Strains for Accelerate Diagnostics Licensing

This technology includes a repository of unique Enterobacteriaceae isolates for various therapeutic and diagnostic uses:

Enterobacter cloacae (Known Acquired Resistance: NDM-1) – Strain 0038

Klebsiella pneumoniae (Known Acquired Resistance: CTX-M-14) – Strain 0079

Citrobacter freundii (Known Acquired Resistance: KPC-2) – Strain 0116

Escherichia coli (Known Acquired Resistance: NDM-1) – Strain 0118

Klebsiella pneumoniae (Known Acquired Resistance: NDM-1) – Strain 0148

Escherichia coli (Known Acquired Resistance: NDM-5) – Strain 0150

Streptococcus pneumoniae Invasive and Non-invasive Clinical Isolates for Various Diagnostic and Therapeutic Uses

This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.

Development of LEAPS Technology in Enhancing Immune Response Against Influenza Virus Infection

The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system's response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there's a marked improvement in the immune system's ability to fight off the virus.

Methods of making and using dopamine receptor selective antagonists/partial agonists

Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse.  Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors.  The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use disorders (e.g. cocaine and opioid), schizophrenia and depression.